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Abstract
Despite some notable successes in the control of infectious diseases, transmissible pathogens still 
pose an enormous threat to human and animal health. The ecological and evolutionary dynamics 
of infections play out on a wide range of interconnected temporal, organizational and spatial 
scales, which even within a single pathogen often span hours to months, cellular to ecosystem 
levels, and local to pandemic spread. Some pathogens are directly transmitted between individuals 
of a single species, while others circulate among multiple hosts, need arthropod vectors, or can 
survive in environmental reservoirs. Many factors, including increasing antimicrobial resistance, 
increased human connectivity, and dynamic human behavior, raise prevention and control from 
formerly national to international issues. In the face of this complexity, mathematical models offer 
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essential tools for synthesizing information to understand epidemiological patterns, and for 
developing the quantitative evidence base for decision-making in global health.
Introduction
Thirty-five years ago, there was a belief that the health burden of infectious diseases was 
close to becoming insignificant, as our means of defense and control, including hygiene, 
nutrition, drugs and vaccines, had brought about a steady decline in overall mortality (1). In 
recent decades, however, it has become clear that the threat persists in our rapidly changing 
world, and human mortality attributed to infection is now projected to remain at current 
levels of 13–15 million deaths annually until at least 2030 (2). Successes in eradicating 
smallpox and rinderpest have been isolated events in a landscape of endemic and epidemic 
infections (3). Newly emerging infectious agents represent a continuing challenge, for 
example HIV in the 20th century, more recently SARS- and MERS-coronavirus, West Nile 
Virus, Nipah virus, drug resistant pathogens, novel influenza-A strains, and a major Ebola 
outbreak in 2014. Most new infections enter the human population from wildlife or 
livestock, and the possibilities for emergence and spread in the coming decades are likely to 
increase due to population growth, increased urbanization and land changes, greater travel, 
and increased livestock production to meet demands from the world’s expanding population 
(4–8). In our modern world of instant communication the changing behavior of individuals, 
often in response to publicity about epidemics (as in the case of the SARS epidemic, H5N1 
and H7N9 avian influenza, or recent Ebola and MERS outbreaks) or social media attention, 
is a key issue (9,10). Phylogenetic data shed light on an additional layer of complexity (11), 
as will an increased understanding of the human genome and how it influences factors such 
as susceptibility, infectiousness and its duration. At the same time, the development of 
effective new vaccines remains a difficult challenge, especially for antigenically very 
variable pathogens (e.g., HIV, falciparum malaria) and for pathogens that stimulate 
immunity that is only partly protective (e.g., Mycobacterium tuberculosis) or temporary 
(e.g., Vibrio cholerae).
In the face of this complexity, computational tools (Box 1) are essential for synthesizing 
information to understand epidemiological patterns, and for developing and weighing the 
evidence base for decision-making. Here, we review the contribution of these tools to our 
understanding of infectious disease dynamics for public health, concentrating both on 
selected illustrative examples and on current developments. We argue that experts on 
infectious disease dynamics and experts on prevention and control need to collaborate 
closely on a global scale, to improve decision making concerning veterinary and human 
public health as well as agricultural health, both for current infectious disease challenges and 
for those that lie ahead. Quantitative analysis should be part of all public health policy 
formulation when addressing the control of infectious diseases.
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Box 1
Quantitative tools in infectious disease dynamics
Here, we use the words “computational tools” loosely. In infectious disease dynamics, 
there is a broad range of relevant quantitative tools and we refer to the entire collection. 
This comprises first of all statistical methods for inference directly from data, including 
methods to analyze sequencing and other genetic data. This leads to estimates of 
important epidemiological information such as length of latency, incubation and 
infectious periods and their statistical distributions, inferred transmission chains and trees 
early in outbreaks, the risks related to various transmission routes, or estimates of rates of 
evolution. Mathematical models in the strict sense refer to mathematical descriptions of 
processes thought to be associated with the dynamics of infection, for example in a 
population or within an individual. Such models take many forms, depending on the level 
of biological knowledge of processes involved and data available. Such models also have 
many different purposes, influencing the level of detailed required.
Several classes of model are used, spanning the spectrum of information available. At 
one end of the range are detailed individual-based simulation models, where large 
numbers of distinct individual entities (with their own characteristic traits such as age, 
spatial location, sex, immune status, risk profile, behavior pattern) are described in 
interaction with each other, possibly in a contact network, and with the infectious agent. 
At the other end, there are compartmental models where no individuals are recognized, 
but only states for individuals (for example: susceptible, infectious, immune) aggregated 
into compartments where everyone has the same average characteristics, and where 
interaction is typically random (everybody mixes with everybody else). Such models do 
not describe the disease history of single individuals, but rather the time evolution of 
aggregated variables, such as the number of individuals that are currently susceptible. 
Mathematical models can have both mechanistic parts in their description, based on 
assumptions about biological mechanisms involved, and more phenomenological parts, 
where there is a statistical or presumed relation between variables, without clear 
assumptions from which this relation can be derived. An example of the former is the 
assumption of mass action to describe interaction between individual hosts; an example 
of the latter is an empirical relation between the length of an infectious period in a 
mosquito and environmental temperature.
For infectious disease dynamics, our world is clearly stochastic, in that chance events 
play a role in many of the processes involved. Certainly at lower levels of biological 
aggregation, chance dominates, for example in infection of individual cells or in contacts 
individual hosts make. At higher aggregation levels, many cells or individuals interact, 
and chance effects may average out to allow deterministic descriptions. There are purely 
stochastic models, purely deterministic models, and models that are mixed. It is 
important to point out that, even though the world is stochastic, that stochastic 
descriptions are not by definition better than deterministic descriptions. Both are still 
models of reality, and the fact that chance plays a role may have a far less significant 
influence on model outcome and prediction than choices made in the relations between 
ingredients and variables.
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Areas of rapid growth are statistical and numerical methods and tools to estimate model 
parameters from, often scarce, mismatched or incomplete, data, and to contrast model 
output with real world observations.
Models and public health policy formulation
The value of mathematical models to investigate public health policy questions was 
recognized at least 250 years ago when, in 1766, Daniel Bernoulli addressed an important 
public health controversy at the time and published a mathematical analysis of the benefits 
of smallpox inoculation (then called variolation) (12). Since then, and particularly over the 
past 50 years, the study of infectious disease dynamics has grown into a rich 
interdisciplinary field. It is driven both by the desire for fundamental understanding and the 
need to use that understanding to aid public health decision making. Decision making on 
vaccination strategies, for example, increasingly depends on model analyses, where 
infection dynamics must be combined with cost data (Box 2, Influenza: prevention & 
control). In recent decades, response to major infectious disease outbreaks including HIV, 
BSE, Foot and Mouth Disease (FMD), SARS, and pandemic and avian influenza, have 
shown both the need for and capabilities of models (Box 3, HIV: Test & treat strategy). 
Model-based analysis of such outbreaks also continually pinpoints areas for improvement in 
methodology and data, emerging from comparison of predictions of models with observed 
patterns.
Box 2
Influenza - prevention and control
Human influenza – pandemic and seasonal – remains a major issue in public health due 
to the continued emergence of novel genetic strains, and one where models have 
successfully addressed questions from basic biology to epidemiology and health policy. 
In recent years, modeling and other quantitative analysis has been used to study at least 
three major issues: pandemic preparedness and mitigation strategies (84–89), rethinking 
vaccination strategies for seasonal influenza (70), and improved methods in 
phylodynamics and influenza strain evolution (11). Recent models of influenza fitness 
have also been developed to predict viral evolution from one year to the next, providing a 
principled and more precise method for the vaccine selection required every year (90).
For seasonal influenza, models have played a key role in providing the scientific 
evidence base for vaccination policy, making use of the information in multiple, often 
unavoidably biased, data sources such as syndromic time-series, vaccine coverage and 
efficacy, economic costs, and contact patterns in the population. For example, a 
combined epidemic and economic model was fitted to fine-grained data from many 
sources to describe the dynamics of influenza in the United Kingdom, and the influence 
of previous vaccination programs (70). With confidence in the model’s predictions based 
on its ability to capture past patterns, it was used to look at alternative vaccination 
policies and led to a new national policy to vaccinate school-age children (91). Targeting 
those individuals most likely to spread the virus, rather than only those most likely to 
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suffer the largest morbidity, is a marked departure from established practice in the UK 
and is currently under consideration elsewhere (92).
Box 3
HIV – test & treat
Mathematical modeling has played a central role in our understanding of the HIV 
epidemic, and in informing policy from the outset of our recognition of the pandemic 
(93). Some of the many insights include a model-based analysis of viral load data from 
inhibition experiments, which revealed the rapid and on-going turnover of the within-host 
viral population (94), and the use of phylogenetic models to show that the HIV pandemic 
did not emerge in the 1980s, but had its roots in the early 20th century (95).
A key contribution of mathematical modeling has been to identify when viral 
transmission occurs over the course of infection, which determines the potential to halt 
spread by various measures. Models have shown that transmission of HIV depends on the 
epidemic phase and the sexual behavior of the population, and a large proportion of 
transmissions may occur late in infection (96). Model-based inference in the Netherlands 
also suggested that the effective reproduction number (Box 4) had fallen below one due 
to a combination of low risk behavior and a very effective diagnosis and treatment 
program (97). The debate was transformed in the mid 2000s, when eradication of HIV 
through a ‘test and treat’ strategy was hypothesized (98,99). Subsequent trial results 
showing that antiretroviral treatment (ART) of HIV-positive individuals could practically 
eliminate transmission within sexual partnerships when the index case is treated (100), 
have further supported the role of treatment as prevention. Although these findings have 
not dispelled concerns about transmission early in infection (93), or about extra-couple 
transmission (101), it is suggested that high population coverage of ART may have 
reduced the incidence of HIV infection in rural KwaZulu-Natal, South Africa (102).
These findings, combined with the prospect of cheaper, more effective drugs and delivery 
structures, underpin UNAIDS’ goal of ‘zero new infections’ for HIV and the initiation of 
a multi-million dollar cluster-randomized trial (103), which will have its outcome 
assessed against model predictions. In the meantime, the scientific discussion of the 
effectiveness of ART in preventing transmission continues, sparked by studies that fail to 
show a decline in incidence after increased treatment (104). Such debates are essential to 
elucidate areas for improvement of the models used, data needs for such improvement, 
and to highlight methodological limitations (105). Notably, one can argue that individual-
level characteristics, behavior and decisions may be important in determining success. 
This will demand more refined stochastic models capturing many sources of 
heterogeneity concomitant with the acquisition of more refined data. As in many areas of 
science and engineering, a law of diminishing returns in understanding can operate with 
the representation of increased complexity, but as models increasingly aspire to provide 
quantitative as well as qualitative predictions, the representation of many heterogeneities 
may be necessary.
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Box 4
Some fundamental terms and concepts
• susceptible – individual who is at risk of becoming infected if exposed to an 
infectious agent.
• basic reproduction number, R0 - average number of infections caused by a 
typical infected individual in a population consisting only of susceptibles; if R0 
> 1, the infectious agent can start to spread.
• effective reproduction number, Re – average number of infections caused by a 
typical infected individual when only part of the population is susceptible; as 
long as Re > 1, the agent can continue to spread.
• herd immunity – state of the population where the fraction protected is just 
sufficient to prevent outbreaks (Re < 1).
• critical elimination threshold, pc - proportion of the susceptible population that 
needs to be successfully protected, for example by vaccination, to achieve herd 
immunity; pc = 1 − 1/R0 is a rule of thumb from models when hosts are assumed 
to mix randomly.
• force of infection – per capita rate at which susceptible individuals acquire 
infection.
• final size – fraction of the initial susceptible population that eventually becomes 
infected during an outbreak.
• prevalence – proportion of the population with infection or disease at a given 
time point.
• super-spreader/super-shedder - infected individual that produces substantially 
more new cases than the average because of greater infectiousness, longer 
duration of infectiousness, many more transmission opportunities/contacts, or 
combinations of these. Even when the average R0 is relatively small, these 
individuals have large effects on outbreaks.
• metapopulation – collection of populations, separated in space, but connected 
through movement of individuals.
• critical community size – minimum number of individuals in a population that 
allow an infectious agent to persist without importation of cases.
• case fatality ratio – proportion of symptomatic infections that result in death.
• SIR model – most basic model metaphor for immunizing infections where each 
living individual is assumed to be in one of three epidemiological states at any 
given time: Susceptible, Infected & infectious, and Recovered & immune. The 
model specifies the rates at which individuals change their state. Individuals 
progress from S to I when infected, then from I to R upon recovery. Many 
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variants exist, for example recognizing different classes of S, I and R 
individuals, depending on individual traits such as age.
For infectious agents important to public health, ‘case law’ has built up, for example 
regarding important factors for infection dynamics, concepts to aid understanding and 
communication of quantitative and qualitative insight, and regarding computational tools 
and modeling frameworks (Table 1 and Box 4). The basic reproduction number R0 is a 
central concept characterizing the average number of secondary cases generated by one 
primary case in a susceptible population. Such concepts serve to highlight what must be 
measured to interpret observed patterns and to quantify the impact of control strategies in a 
cycle of interaction between policy and modeling (Fig. 1).
Two fundamental properties of the world that shape infectious disease dynamics make 
computational tools key for understanding reality. The world is essentially a stochastic and 
highly non-linear system. The non-linearity not only derives from the complex interaction 
between factors involved in transmission are complicated, but also from the influence that 
the infection process has on the distribution of important characteristics at various temporal 
and spatial scales. For example, the age-related nature of infection and mortality in HIV 
changes the age distribution of the population, and previous exposure to strains of influenza 
alters the distribution of influenza susceptibility. Such feedback mechanisms contribute to 
the high nonlinearity of infection processes. Non-linearity leads to counterintuitive 
phenomena (Fig. 2), and the inability simply to extrapolate experience from one situation to 
another (for example when deciding whether to implement a vaccination policy in different 
countries, Fig. 1). Mathematical tools, relating to data and processes on a large range of 
interacting scales, have become essential to explore, anticipate, understand and predict the 
effects of feedbacks within such complex systems, including changes caused by 
intervention.
Current and future opportunities for models in public health
Over the last decade, key public health questions, ranging from emergence to elimination, 
have posed a range of challenges for modeling infectious disease dynamics, many of which 
rest on leveraging novel data sources, and integrating data from a range of scales - from 
sequence data to global circulation. Given commonalities in processes across pathogens, 
progress made in one area can lead to advances in another, and progress in the areas 
described above all build on and inform each other, making this a dynamic time for research 
in the discipline (13). A few themes are chosen to illustrate current trends in model 
development and public health application.
The difficulties of real-time outbreak modeling: the Ebola 2014 outbreak
The ongoing (at the time of writing) outbreak of Ebola in West Africa serves to highlight 
both opportunities and challenges in modeling for public health. In the initial phase of an 
outbreak, real-time estimates of the reproduction number or simple exponential 
extrapolation (14) allow short-term predictions of epidemic growth that can be used, for 
example, to plan for necessary bed capacity. Also in an early phase, phylogenetic 
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quantitative tools can use samples from initial victims to provide important estimates of 
outbreak origin (15). Later in an outbreak, these methods are replaced by more detailed 
mechanistic models that explicitly take into account depletion of susceptibles, as well as 
specifics such as different transmission routes or settings, to provide more accurate and fine-
grained predictions of the impact of public health measures. For Ebola, such methods make 
it possible to distinguish between transmission at funerals, in health-care settings and in the 
community (16,17) to predict the effect of increasing bed capacity or reducing funeral 
transmission. Determining which combinations of measures are most effective in bringing 
down the reproduction number call for close and fast interaction between modelers and 
policy makers (18). It is likely that disease-dynamic models will also be at the forefront of a 
debate on the optimal deployment of initially scarce Ebola vaccines, once such vaccines 
become available.
With the opportunities of real-time modeling for public health come specific challenges. The 
imperative to produce reliable and meaningful analysis for those at the forefront of battling 
the outbreak has to be balanced against the pressures and delays of scientific publication. In 
an ongoing outbreak, data can be patchy and reporting delayed, and different data sources 
are not always synthesized. Particularly, data are lacking on the effect on transmission 
dynamics of the various control measures operating simultaneously in the hectic 
circumstances of the most severely hit areas. Also, under-reporting is a critical challenge for 
ongoing assessment of the epidemic and has enormous impact on predictions of outbreak 
size, but also of outbreak impact, for example in terms of the case fatality ratio. This 
estimate of severity suffers early in an outbreak from imprecise information on both the 
numerator (deaths confirmed as being caused by the infection) and the denominator (under-
reporting and not all suspected cases are laboratory-confirmed infections). This caused 
problems early in the H1N1 influenza outbreak starting in Mexico in 2009, as well as in the 
current Ebola outbreak. While levels of under-reporting can be estimated after the outbreak 
from retrospective serological studies, it is usually not identifiable in real-time data.
These limitations make it almost impossible to make reliable long-term predictions. 
Modeling results are therefore often based on scenarios in which a pathogen spreads 
unaltered by behavioral changes or the public health response. In reality this is rarely the 
case, especially in a devastating outbreak such as the one of Ebola in West Africa, where the 
situation constantly changes due to growing awareness in the community, as well as national 
and international intervention. Careful communication of findings is key, and data and 
methods of analysis (including code) must be made freely available to the wider research 
community. Only in this way can reproducibility of analyses and an open exchange of 
methods and results be ensured for maximal transparency and, consequently, benefit to 
public health.
Emergence of novel human pathogens
There is an ever-present hazard that novel human pathogens emerge from livestock and wild 
mammal and bird reservoirs. Research on potential emerging zoonoses draws on concepts 
from across the spectrum of infectious disease dynamics, disease ecology, microbiology and 
phylogenetic analysis. Particular challenges include estimating human-to-human 
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transmissibility against a backdrop of on-going zoonotic spillover, detecting anomalous 
outbreaks, and assessing the risk that more dangerous strains may arise through pathogen 
evolution.
The recently identified gap in methodology for zoonoses with weak human-to-human 
transmission (6) is being filled, with new approaches to estimating R0 and other 
transmission-related quantities from subcritical outbreak data (19–21). These studies address 
key public health concerns, but rely on strong assumptions regarding the quality and 
completeness of case observations. Better information on surveillance program efficacy 
could be gained through serological surveys (where blood and saliva samples reveal 
evidence of past and present infections) or sociological study, and modeling studies can help 
to design and characterize efficient surveillance programs (22). Given the predominance of 
zoonotic pathogens among emerging infections, models for transmission dynamics and 
evolution in multispecies ecosystems and food webs, consisting of host species and non-host 
species interacting ecologically and epidemiologically, are a crucial area for future 
development (6,23). The greatest challenge – and the greatest prize – in modeling emerging 
zoonoses is to assess which diseases pose the most risk to humans and how these might 
change over time and in different localities (24). Such tasks, which will join molecular 
studies to experimental infections to epidemiological and ecological surveys, will drive 
empirical and theoretical efforts for decades to come.
The rising availability of pathogen genome sequence data, coupled with new computational 
methods, presents opportunities to identify with precision ‘who infects whom’ and the 
networks of infection between humans and reservoirs (25). Full realization of this potential, 
though, will require denser and more systematic whole genome sampling of pathogens 
coupled with associated epidemiological data, as well as baseline information on genetic 
diversity and evolutionary rates, especially in animal hosts (26).
Pathogen evolution and phylodynamics
As pathogen genetic data become increasingly available, modelers are finding ways to 
synthesize these new data streams with more traditional epidemiological information in 
phylodynamic tools (27,28). However, current frameworks employ compartmental 
epidemiological models, which do not make efficient use of individual-level 
epidemiological data. Although sampling theory is well developed for standard surveillance 
data, the relationship between a set of pathogen sequences and the phylogeny inferred from 
a population sample is more complex (11). Many-toone mapping possibilities between, on 
the one hand, combinations of epidemiological, immunological and evolutionary processes 
shaping sequences and, on the other hand the inferred phylogeny, demand the integration of 
diverse data sources and an increased focus on systematic sampling.
Phylodynamic studies to date have largely focused on fast-evolving RNA viruses, driven by 
the large amount of data generated for clinical (e.g. Hepatitis C Virus (HCV), HIV) or 
surveillance (e.g. influenza) purposes (11). Replicating these efforts on an expanded array of 
pathogens, including DNA viruses, bacteria, fungi, protozoa (e.g. malaria) and helminths is 
a promising avenue for future research (29). It is of particular importance in the context of 
the evolution and spread of drug resistant variants and escape mutants from vaccine 
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protection. However, genome-wide pathogen data also present challenges, in particular in 
relation to accommodating recombination, re-assortment, and mobile genetic elements. 
Analysis of bacterial genomes usually considers only those genes that are shared across taxa, 
but there are good reasons to believe that non-core genes play an important role in bacterial 
evolution, including the evolution of antibiotic resistance (30).
While sequence data are extremely valuable, in order to link these data fully to disease 
dynamics a key advance will be determining how sequence changes may affect functions 
related to pathogen fitness, such as replication rate, transmissibility, and immune recognition 
(genotype to phenotype). Molecular epidemiological studies often treat pathogen genetic 
variation as simply reflecting the underlying transmission process, whereas in reality such 
variation may play an important role in determining transmission dynamics, as exemplified 
by the escape from herd immunity by influenza A virus (31).
‘Deep’ sequencing of pathogens within individual hosts generates information on within-
host diversity, resulting from evolution within the host (often in response to drug treatment), 
or multiple infections. To tackle within-host diversity, models that embed pathogen 
evolution within a transmission tree are needed. Such models, which cross the within- and 
between-host scales, are only just becoming analytically and computationally feasible 
despite being proposed several years ago (32). Similarly, while progress has been made in 
scaling inference from genes to genomes (33), scaling inference to large numbers of 
sequences is lagging far behind.
Multiple infections
Infectious disease epidemiology evolved by focusing on interactions between a single host 
species and a single infectious agent. It is becoming increasingly clear that multiple agents 
simultaneously infecting the same host populations and individuals significantly add to 
public health burden and complicate prevention and control. Co-infections in relation to 
HIV, for example tuberculosis and HCV, or co-infection of different strains of influenza A 
virus raise important public health and evolutionary issues. Multiple agents infecting the 
same host individual have been shown to influence each other by increasing or decreasing 
susceptibility and/or infectivity of that individual, thereby influencing the population 
dynamics of these agents in ways that we have yet to explore and understand (34,35).
Multiple infections of the same individual with closely related pathogens occur when 
infection elicits no, or only a partial, immune response. Macroparasites including many of 
the important human helminth infections are good examples of pathogens that evade human 
immune responses permitting repeated infection of the same host (36). Biological 
mechanisms giving rise to such multiple infections include sequential reinfections caused by 
antigenic drift in influenza, antigenic variation in respiratory syncytial virus (RSV) and 
waning (slow loss of) immunity in pertussis while lack of cross-protection in many 
colonizing microparasites, for example pneumococcus and human papilloma virus (HPV), 
allows for multiple concurrent infections. Although the existence of reinfections is a clinical 
fact, population-level data are scarce as reinfections are often subclinical and individual-
based longitudinal infection-histories only anecdotal. Results from new analytic approaches 
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relating to deep sequencing and neutralization tests covering multiple antigens are being 
utilized (37).
The immunodynamics of influenza have clear policy implications for the identification of 
high-risk groups in connection with pandemic planning (38) while the dynamics of waning 
immunity are key to the current concerns about immunization level for pertussis (39). 
Multivalent vaccines covering only a targeted subset from the circulating strains of 
pneumococcus and HPV pose important new applied problems (40). The spread of 
recombinant viruses implies the existence of multiple infections. An example is the Sydney 
2012 strain of norovirus, but how this can occur in an acute infection remains to be 
understood, as the time window for multiple exposure is limited. Mathematical models may 
help to explore how, for example, a subpopulation with chronic infection or a hypothesized 
environmental reservoir may contribute to the dynamics of multiple infections.
Behavior of hosts
Human behavior is a fundamental determinant of infectious disease dynamics, whether by 
affecting how people come in contact with each other, vaccination coverage, reporting 
biases, or adherence to treatment. Traditional epidemic models have tended to ignore 
heterogeneity in contact behavior (although early HIV models addressed heterogeneity in 
sexual behavior by necessity (41)), however increasing sophistication of contact network 
models (42), together with data on epidemiological contacts, creates opportunities for 
understanding and controlling transmission at a fundamental level (43), and opens up the 
possibility of independent study of relevant social factors (10). Recent years have seen 
exciting developments in the measurement of contact patterns and ‘who might infect whom’ 
through advances in individual electronic identification technology. This is a promising 
avenue for linking pathogen genetic data and human behavior.
Contact patterns are not static, and can shift during outbreaks as individuals change their 
behavior in response to perceived risk and public-health interventions (44). Modeling has 
illuminated this process, for example incorporating peer influence on vaccination behavior 
into models of infectious disease dynamics (45,46). Analysis of data from online social 
networks has also created promising opportunities to validate such approaches with 
empirical observations (47,48).
Movement and travel are tightly linked to the spread of infection, and have been explored 
through models to highlight commuting and agricultural migration driving local disease 
transmission (49), and global disease patterns through air travel (50). These processes are 
now being investigated to gain insights into the more complex case of vector-borne diseases 
such as malaria and dengue, where both host and vector movement can interact to drive 
local (51) and large-scale dynamics (52).
Elimination/eradication
Modeling has long provided support for elimination efforts – vector control (53), critical 
community size (54), herd immunity and critical vaccination threshold (55,56) were all 
powerful insights from models framed in relatively simple and homogenous terms. 
Subtleties and complexities in many current eradication programs, as well as the availability 
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of novel data sources, have called for a range of extensions in the theory. As we approach 
elimination targets, disease dynamics have changed in ways that were largely predicted by 
models, but also in unanticipated ways due to ignorance about key epidemiological 
processes.
Incentives for control efforts also change, both at the individual level (passive or active 
refusal can develop (57)) and at the country level (58). This reinforces the call for 
development of models of human behavior and its interaction with infectious disease 
dynamics (9), potentially drawing on new data sources (e.g. from social media (59,60)), as 
well as for models that can capture national and non-governmental motivations, interactions 
and competition, economical or otherwise. Long-term control puts pathogens under strong 
selection for resistance, calling for evolution-proof control methods (61) and novel vaccine 
technologies and their optimized delivery (62).
Finally, since the era of smallpox eradication, patterns of global disease circulation have 
changed radically. Human mobility and migration are increasing global connectivity, 
strengthening the need for cooperation and international synchronization of efforts (as 
illustrated by polio). Techniques for analysis of novel data-sources are again key here, e.g., 
Call Data Records provide unique opportunities to understand disease source-sink dynamics 
(52).
Computational statistics, model fitting and big data
By definition and design, models are not reality. The properties of stochasticity and non-
linearity strongly influence the accuracy of absolute predictions over long time horizons. 
Even if the mechanisms involved are broadly understood and relevant data are available, 
predicting the exact future course of an outbreak is impossible due to changes in conditions 
in response to the outbreak itself, and due to the many chance effects in play. These 
stochastic effects dominate developments in situations with relatively few infected 
individuals (such as at emergence, approaching the threshold for sustained host-host spread, 
or approaching elimination/eradication). This makes it virtually impossible to predict which 
infectious disease agent is going to emerge/evolve next and where, or to predict when and 
where the next or last case in an outbreak will occur. There is, typically in complex systems, 
a fundamental horizon beyond which accurate prediction is impossible. The field has yet to 
explore where that horizon is and whether computational tools and additional data (and if so 
which data) can stretch predictions to this limit. In contrast, ‘what-if’ scenarios for public 
health intervention can provide qualitative (and increasingly semi-quantitative) insight into 
their population consequences.
With growing applications in public health there is an increasing demand to validate models 
by making model predictions consistent with observed data. The development of evermore-
powerful computers is accompanied by new techniques utilizing this power, notably for 
statistically rigorous parameter estimation and model comparison. Techniques such as 
Markov Chain Monte Carlo (MCMC) have become firmly established tools for parameter 
estimation from data in infectious disease models (e.g. 63), and Monte Carlo based methods 
will play a pivotal role in addressing the challenges that lie in reconciling predictions and 
observations (64,65). Other techniques, such as so-called particle filters, approximate 
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Bayesian computation, emulation, and their combinations with MCMC (e.g. 66), are rapidly 
developing and allow matching stochastic models that explicitly account for incomplete 
observations to time series of cases, giving insights into scenarios as diverse as cholera in 
Bangladesh (67) and influenza (68,69). The need to integrate multiple data sources (70,71) 
as well as to include uncertainty in model parameters and/or structure has led to an increase 
in the popularity of Bayesian approaches.
The rapid expansion of infectious disease models and their application over the past decade 
has coincided with an increase in open access datasets available from a variety of sources, 
but progress in data capture needs to be accelerated. While some of these technologically 
advanced data streams have been incorporated into models, for example to track the 
incidence of influenza in the USA (72), to elucidate the spatial dynamics of measles and 
malaria in Africa (53,73) and to chart the spread of dengue globally (74), much more 
remains to be done to leverage data collected from different sources (e.g. demographic, 
genetic, epidemiological, treatment and travel patterns) and at different temporal and spatial 
scales.
Concluding remarks
Infectious diseases are an important frontier in public health, and their prevention and 
control call for global, rather than national or regional, coordinated efforts (75–78). The 
success of smallpox and rinderpest eradication campaigns shows the possibilities; the global 
spread of newly emerged pathogens (recently avian influenza strains and MERS 
coronavirus), the difficulties in curbing the spread of antibiotic resistance, the upsurge of 
polio towards the ‘end-phase’ of its eradication, and the recent unprecedented spread of 
Ebola virus, are examples that show the need for international coordination and 
collaboration. Non-linearity in infectious disease dynamics and global connectivity cause 
sub-optimal national decisions on control and prevention to have regional and even global 
repercussions.
Given the mismatch with regions where most expertise on infectious disease dynamics is 
concentrated, it is important to empower local scientists and policy makers in regions where 
the burden of disease is heaviest about problems facing their own countries and the 
consequences of local actions. It is essential to make expertise, data, models, statistical 
methods and software widely available by open access. There are several initiatives (e.g. 
Thiswormyworld.org, Garkiproject.nd.edu, EDENextdata.com, and the Malaria Atlas 
Project), but much more needs to be done. Modeling tools and software for data analysis are 
beginning to become open source, such that findings can be replicated, additional scenarios 
can be evaluated, and others can incorporate methods for data analysis or simulation. 
Ultimately, sharing models guarantees more reproducible results, while maximizing model 
transparency.
Making data sets widely available is also crucial, for example to support replication of 
findings and broader comparative analyses (79). As models become open access, so should 
much of the data collected by governments, international agencies and epidemiology 
research groups. Two outbreaks never occur in exactly matching circumstances, even for the 
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same infectious agent, so there is potential to study many outbreaks in parallel to gain 
insight into the determinants of outbreak pattern and severity. Looking forward, there is a 
major opportunity to design experiments, clinical trials (for example for vaccines (80)), and 
surveillance protocols to test model predictions or assumptions, and to help reduce or better 
target the enormous costs involved. By integrating modeling approaches throughout the full 
life cycle of infectious disease policies, including economic considerations (58, 70, 81), 
health outcomes can be improved and scientific understanding can be advanced.
At present, the evidence provided by infectious disease models is not considered on the 
GRADE scale (www.gradeworkinggroup.org) alongside that of conventional studies such as 
clinical trials. Regardless, models are essential when diverse sources of data (including 
GRADE-scale evidence) need to be combined and weighed. In many cases, the definitive 
trial cannot be performed and models are needed to catalyze insight and extract maximum 
value from data that are available. In recent years, uniformity of practice and quality control 
for models has received more attention, resulting in initial attempts to characterize Good 
Modelling Practice for infectious diseases (82,83).
The optimal use of models to inform policy decisions requires a continuous dialogue 
between the multidisciplinary infectious disease dynamics community and decision makers. 
This is increasingly understood by governments in developed countries, in non-
governmental agencies and by large funding bodies such as the Bill and Melinda Gates 
Foundation. This dialogue will help to reduce the burden from infectious diseases by 
providing better-informed control strategies. Mathematical models will allow us to capitalize 
on new data streams, and lead to an ever-greater ability to generate robust insight and 
collectively shape successful local and global public health policy.
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Figure 1. 
Example of the process of modeling for public health, based on rubella. Policy questions are 
formulated; available data are brought to bear on the question, here illustrated by incidence 
of rubella following the introduction of vaccination in individuals aged less than 15 years, or 
15 or more years in Costa Rica (127). Scientific understanding and subsequent policy advice 
is derived from model-based analyses of data, in this case using a non-linear age-structured 
SIR model (see Box 4), and can lead to collection of key missing data for model 
improvement. A plot illustrates insight where each square depicts a combination of birth rate 
and infant vaccine coverage (reflecting the situation in different countries, e.g. Somalia, 
diamond, Nepal, circle) for routine vaccination only. The color of the square indicates the 
confidence in the true value of R0 being higher (red) or lower (green) than a critical value 
that depends on birth rate and coverage. This translates into confidence that the public health 
burden caused by the rubella-complication of Congenital Rubella Syndrome (CRS) in 
newborns is likely to be reduced (green) compared to the situation without vaccination 
(128), suggesting that introduction of routine measles-rubella (MR) vaccine in Nepal is 
likely to succeed in bringing down CRS, while in Somalia routine MR vaccine would 
increase CRS burden without substantive improvements in the fraction that is vaccinated.
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Figure 2. 
Examples of counter-intuitive effects of non-linear infection dynamics. Upper left graph: 
Non-linear interaction between prevalence of a helminth infection and infection pressure (as 
measured by the mean intensity of existing infections) means that control measures must 
have a disproportionately large impact on intensity before prevalence is reduced. This effect 
is predicted by a mathematical model (solid line) and corroborated by field data (crosses) 
(129). Upper right graph (adapted from 130): Non-linear relation between total number of 
cases of congenital rubella syndrome (CRS) and rubella vaccine coverage, showing that sub-
optimal levels of vaccine coverage cause worse health outcomes than no vaccination. The 
line shows model predictions; similar effects have been documented for real rubella control 
situations (131). Middle graphs (from 132): Modeling results of rebound of gonorrhea 
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transmission with different treatment strategies without (left panel) and with (right panel) 
antimicrobial resistance developing. In the presence of resistance, focusing treatment on the 
high-risk core group leads to an increase to un-treated baseline prevalence, after initially 
strong decline for more than a decade. Bottom graphs (from 133): Field data and box plot of 
a non-linear relation between R0 for dengue transmission and average dengue hemorrhagic 
fever incidence across Thailand, showing that starting control that brings down transmission 
from a situation with high R0 may paradoxically increase cases of DHF.
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Table 1
As different infections have become the focus of public health attention, the modeling community has 
responded by developing improved concepts and methods. The table concentrates on the period since 1950. 
The first column lists the (classes) of infection, the second column lists factors whose importance to infection 
dynamics became particularly clear in relation to those infections; the third and fourth columns highlight 
concepts and methods that were developed in response. For each row, only a few typical references are given. 
Many factors, concepts and methods are relevant, in current use, and in continual development for much larger 
classes of infectious agents.
Motivating studies Important factors Concepts Methods
Malaria
(1910s, 1950s onwards, 
53,106,107)
Transmission via insect vectors; 
nonlinear dependence of 
transmission on mosquito biting 
rate; influence of environmental 
and climatic variables.
Threshold for control, basic 
reproduction number.
Models with two host species 
(host-vector models); using 
models to support and guide field 
campaigns; relating models to 
field data.
Childhood infectious diseases, 
e.g. measles.
(1950s onwards, 54,108)
Immunizing infections; spatial and 
temporal heterogeneity; 
demography; age structure; 
household structure.
Critical community size and 
herd immunity; periodic 
outbreaks; fade out; vaccine 
efficacy.
SIR models; age-structured 
models; models with periodic 
forcing; spatial and stochastic 
models; metapopulation models; 
time-series models.
Macroparasites.
(1970s onwards, 108)
Clumped infections, multi-strain 
and multi-species infections, cross 
immunity, concurrent infections.
Consequences of 
overdispersed distribution of 
parasite load (Figure 1)
Stochastic models, approximations 
including hybrid models and 
moment closure.
Sexually transmitted infections, 
e.g. HIV.
(1980s onwards, 108,109)
High/low risk groups; non-random 
contact structure; partnerships; 
within-host strain diversity and 
evolution; time scale.
Incubation and infectious 
period distribution; core 
group; next-generation 
matrix and operator; 
partnership dynamics.
Statistical methods (e.g. back 
calculation); Models with 
(dis)assortative mixing; pair 
formation models; within-host 
dynamic models.
Veterinary outbreaks, e.g. BSE 
and FMD.
(1990s onwards, 110,111)
Fixed spatial locations with 
changing contact networks.
Local versus long-range 
transmission; spatial 
intervention (ring 
vaccination/culling); conflict 
of priorities at different 
scales.
Individual based models and 
spatial simulations (FMD); data-
driven real-time modeling; 
inference of transmission trees.
Novel emerging infections, e.g. 
SARS, Nipah virus, MERS.
(2000 onwards, 6,112–115)
Behavior change; global inter-
connectedness and international 
cooperation in control; responses in 
absence of biomedical measures; 
animal reservoirs.
Zoonotic spillover; stuttering 
chains; importance of index 
case; super-spreaders; 
unobserved dynamics in an 
animal reservoir; super-
shedding
Contact tracing; modeling 
international spread and control; 
quarantine and case isolation; 
individual heterogeneity in 
infectiousness, incubation and 
latency period.
Influenza including avian 
influenza.
(Present, 27,28,116–118)
Distribution of prior immunity; 
within-population and species 
strain differences, virus evolution 
and interaction; role of wildlife and 
farm animals.
Pandemics; spillover 
between wild birds, and 
farmed birds; 
phylodynamics.
Interaction between 
immunological and 
epidemiological dynamics; 
integrating phylogenetic and 
epidemic methods and models.
Vector-borne diseases, e.g. 
dengue, malaria.
(Present, 119–122)
The influence of climate and 
environment on vector and 
pathogen development; animal 
reservoirs; interaction between 
strains within-host and between-
host.
Dilution effect and role of 
biodiversity in infectious 
disease dynamics; re-
emerging infections.
Evolutionary impact of vaccines/
other interventions; synthesis of 
data from ecology and 
epidemiology; elimination 
modeling; statistical modeling of 
environmental vector suitability.
Bacterial infections, e.g. 
pneumococcal disease, MRSA 
and tuberculosis.
(Present, 39,123–126)
Antibiotic/drug resistance; adaptive 
dynamics.
Vaccine effectiveness; 
interacting natural immunity 
and vaccine boosting.
Modeling interacting and 
emerging strains; stochastic 
models in small populations.
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